Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.

Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY.

Neuro Oncol. 2020 Jan 24. pii: noaa015. doi: 10.1093/neuonc/noaa015. [Epub ahead of print]

PMID:
31974566
2.

Top Ten Tips Palliative Care Clinicians Should Know When Caring for Patients with Brain Cancer.

Kluger BM, Ney DE, Bagley SJ, Mohile N, Taylor LP, Walbert T, Jones CA.

J Palliat Med. 2019 Oct 15. doi: 10.1089/jpm.2019.0507. [Epub ahead of print]

PMID:
31613698
3.

Electrical and thermal conductivities of polycrystalline platinum nanowires.

Wang J, Yu H, Walbert T, Antoni M, Wang C, Xi W, Muench F, Yang J, Chen Y, Ensinger W.

Nanotechnology. 2019 Nov 8;30(45):455706. doi: 10.1088/1361-6528/ab37a7. Epub 2019 Aug 1.

PMID:
31370046
4.

Clinical and research applications of a brain tumor tissue bank in the age of precision medicine.

Snyder J, Poisson LM, Noushmehr H, Castro AV, deCarvalho AC, Robin A, Mukherjee A, Lee I, Walbert T.

Per Med. 2019 Mar;16(2):145-156. doi: 10.2217/pme-2018-0102. Epub 2019 Feb 28.

5.

Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life.

Nassiri F, Price B, Shehab A, Au K, Cusimano MD, Jenkinson MD, Jungk C, Mansouri A, Santarius T, Suppiah S, Teng KX, Toor GS, Zadeh G, Walbert T, Drummond KJ; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i32-i43. doi: 10.1093/neuonc/noy152.

6.

Education Research: Electronic patient portal enrollment and no-show rates within a neurology resident clinic.

Shah K, Alshammaa A, Affan M, Schultz L, Walbert T, Zaman I.

Neurology. 2019 Jan 1;92(1):50-54. doi: 10.1212/WNL.0000000000006685.

PMID:
30584078
7.

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.

Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R.

Neuro Oncol. 2019 Jan 1;21(1):106-114. doi: 10.1093/neuonc/noy091.

8.

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 Jun 29;16(1):179. doi: 10.1186/s12967-018-1552-1.

9.

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6. Erratum in: J Transl Med. 2018 Jun 29;16(1):179.

10.

Cerebral edema induced by laser interstitial thermal therapy and radiotherapy in close succession in patients with brain tumor.

Maraka S, Asmaro K, Walbert T, Lee I.

Lasers Surg Med. 2018 Sep;50(9):917-923. doi: 10.1002/lsm.22946. Epub 2018 May 25.

PMID:
29799137
11.

Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.

Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago OR, Hogan DJ, Gammon D, Kasahara N, Kheoh T, Jolly DJ, Gruber HE, Das A, Walbert T.

Neuro Oncol. 2018 Sep 3;20(10):1383-1392. doi: 10.1093/neuonc/noy075.

12.

The safety of magnetic resonance imaging-guided laser interstitial thermal therapy for cerebral radiation necrosis.

Rammo R, Asmaro K, Schultz L, Scarpace L, Siddiqui S, Walbert T, Kalkanis S, Lee I.

J Neurooncol. 2018 Jul;138(3):609-617. doi: 10.1007/s11060-018-2828-2. Epub 2018 Mar 13.

PMID:
29536345
13.

Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative.

Dirven L, Armstrong TS, Blakeley JO, Brown PD, Grant R, Jalali R, Leeper H, Mendoza T, Nayak L, Reijneveld JC, Le Rhun E, Walbert T, Weller M, Wen PY, Taphoorn MJB.

Lancet Oncol. 2018 Mar;19(3):e173-e180. doi: 10.1016/S1470-2045(18)30004-4. Review.

PMID:
29508764
14.

Simultaneous care in neuro-oncology.

Pace A, Walbert T.

Neuro Oncol. 2018 Feb 19;20(3):302-303. doi: 10.1093/neuonc/nox235. No abstract available.

15.

Maintaining quality of life near the end of life: hospice in neuro-oncology.

Walbert T.

Neuro Oncol. 2018 Mar 27;20(4):439-440. doi: 10.1093/neuonc/nox236. No abstract available.

16.

Brain metastasis: clinical manifestations, symptom management, and palliative care.

Noh T, Walbert T.

Handb Clin Neurol. 2018;149:75-88. doi: 10.1016/B978-0-12-811161-1.00006-2. Review.

PMID:
29307363
17.

Palliative Care, End-of-Life Care, and Advance Care Planning in Neuro-oncology.

Walbert T.

Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1709-1726. doi: 10.1212/CON.0000000000000538. Review.

PMID:
29200118
18.

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26.

19.

Recent Advances in the Classification and Treatment of Ependymomas.

Leeper H, Felicella MM, Walbert T.

Curr Treat Options Oncol. 2017 Aug 10;18(9):55. doi: 10.1007/s11864-017-0496-7. Review.

PMID:
28795287
20.

Managing Glioblastoma in the Elderly Patient: New Opportunities.

Snyder J, Walbert T.

Oncology (Williston Park). 2017 Jun 15;31(6):476-83. Review.

21.

The role of tumor board conferences in neuro-oncology: a nationwide provider survey.

Snyder J, Schultz L, Walbert T.

J Neurooncol. 2017 May;133(1):1-7. doi: 10.1007/s11060-017-2416-x. Epub 2017 Apr 18.

PMID:
28421461
22.

Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.

Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D.

Neuro Oncol. 2017 Jun 1;19(6):845-852. doi: 10.1093/neuonc/nox020.

23.

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.

Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, Walbert T, Chu A, Das A, Diago OR, Gammon D, Gruber HE, Hanna M, Jolly DJ, Kasahara N, McCarthy D, Mitchell L, Ostertag D, Robbins JM, Rodriguez-Aguirre M, Vogelbaum MA.

Sci Transl Med. 2016 Jun 1;8(341):341ra75. doi: 10.1126/scitranslmed.aad9784.

24.

Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American survey.

Walbert T, Glantz M, Schultz L, Puduvalli VK.

J Neurooncol. 2016 Jan;126(2):337-45. doi: 10.1007/s11060-015-1973-0. Epub 2015 Oct 30.

25.

End-of-life care in patients with primary malignant brain tumors: early is better.

Walbert T, Pace A.

Neuro Oncol. 2016 Jan;18(1):7-8. doi: 10.1093/neuonc/nov241. Epub 2015 Sep 29. No abstract available.

26.
27.

Palliative and supportive care for glioma patients.

Walbert T, Chasteen K.

Cancer Treat Res. 2015;163:171-84. doi: 10.1007/978-3-319-12048-5_11. Review.

PMID:
25468232
28.

Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2.

Walbert T, Mendoza TR, Vera-Bolaños E, Acquaye A, Gilbert MR, Armstrong TS.

J Neurooncol. 2015 Jan;121(2):341-8. doi: 10.1007/s11060-014-1638-4. Epub 2014 Oct 31.

PMID:
25359395
29.

Through the patient's eyes: the value of a comprehensive brain tumor center.

Robin AM, Walbert T, Mikkelsen T, Kalkanis SN, Rock J, Lee I, Rosenblum ML.

J Neurooncol. 2014 Sep;119(3):465-72. doi: 10.1007/s11060-014-1494-2. Epub 2014 Jul 16. Review.

PMID:
25026994
30.
31.

End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review.

Walbert T, Khan M.

J Neurooncol. 2014 Apr;117(2):217-24. doi: 10.1007/s11060-014-1393-6. Epub 2014 Feb 13. Review.

PMID:
24522718
32.

Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas.

Ellezam B, Theeler BJ, Walbert T, Mammoser AG, Horbinski C, Kleinschmidt-DeMasters BK, Perry A, Puduvalli V, Fuller GN, Bruner JM, Aldape KD.

Acta Neuropathol. 2012 Sep;124(3):449-51. doi: 10.1007/s00401-012-1011-7. Epub 2012 Jul 8. No abstract available.

33.

Recurrent high-grade glioma: a diagnostic and therapeutic challenge.

Walbert T, Mikkelsen T.

Expert Rev Neurother. 2011 Apr;11(4):509-18. doi: 10.1586/ern.11.37. Review.

PMID:
21469924
34.

Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.

Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Yung WK, Conrad CA, Bobustuc GC, Colman H, Hsu SH, Bekele BN, Qiao W, Levin VA.

J Neurooncol. 2011 Apr;102(2):273-80. doi: 10.1007/s11060-010-0313-7. Epub 2010 Jul 23.

35.

Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment.

Walbert T, Groves MD.

Future Oncol. 2010 Feb;6(2):287-97. doi: 10.2217/fon.09.167. Review.

PMID:
20146587
36.

The role of chemotherapy in the treatment of patients with brain metastases from solid tumors.

Walbert T, Gilbert MR.

Int J Clin Oncol. 2009 Aug;14(4):299-306. doi: 10.1007/s10147-009-0916-1. Epub 2009 Aug 25. Review.

PMID:
19705239
37.

The impact of Accreditation Council for Graduate Medical Education duty hours, the July phenomenon, and hospital teaching status on stroke outcomes.

Alshekhlee A, Walbert T, DeGeorgia M, Preston DC, Furlan AJ.

J Stroke Cerebrovasc Dis. 2009 May-Jun;18(3):232-8. doi: 10.1016/j.jstrokecerebrovasdis.2008.10.006.

PMID:
19426896
38.

Symptomatic neurocutaneous melanosis and Dandy-Walker malformation in an adult.

Walbert T, Sloan AE, Cohen ML, Koubeissi MZ.

J Clin Oncol. 2009 Jun 10;27(17):2886-7. doi: 10.1200/JCO.2008.21.5830. Epub 2009 Apr 27. No abstract available.

PMID:
19398571
39.

Impact of ACGME standards is yet to be determined.

Walbert T, DeGeorgia M, Alshekhlee A.

Am J Med. 2008 Jun;121(6):e21-2; author reply e23. doi: 10.1016/j.amjmed.2008.01.030. No abstract available.

PMID:
18501213
40.

Health-related quality of life in patients with narcolepsy.

Dodel R, Peter H, Spottke A, Noelker C, Althaus A, Siebert U, Walbert T, Kesper K, Becker HF, Mayer G.

Sleep Med. 2007 Nov;8(7-8):733-41. Epub 2007 May 18.

PMID:
17512797
41.

The socioeconomic impact of narcolepsy.

Dodel R, Peter H, Walbert T, Spottke A, Noelker C, Berger K, Siebert U, Oertel WH, Kesper K, Becker HF, Mayer G.

Sleep. 2004 Sep 15;27(6):1123-8.

PMID:
15532206
42.

Systematic assessment of decision models in Parkinson's disease.

Siebert U, Bornschein B, Walbert T, Dodel RC.

Value Health. 2004 Sep-Oct;7(5):610-26.

43.

Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the limbic system of the rat.

Walbert T, Jirikowski GF, Prüfer K.

Horm Metab Res. 2001 Sep;33(9):525-31.

PMID:
11561211

Supplemental Content

Loading ...
Support Center